Lv7
4070 积分 2022-07-13 加入
Refining therapeutic targeting of interleukin-6 by signalling mode selectivity
4天前
已完结
Discovery and Optimization of AMT‐676, a CDH17‐Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers
16天前
已完结
Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
24天前
已完结
Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
29天前
已完结
The next generation of antibody–drug conjugates
1个月前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
1个月前
已完结
Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology
1个月前
已完结
Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: A focus on exposure-response analyses
3个月前
已完结
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
4个月前
已完结
Misconceptions among medicinal chemists regarding ADME and PK optimization
4个月前
已完结
皖公网安备34019202002308
